Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study

Exclusion Criteria

• •Patients already under any Renin-Angiotensin-Aldosterone System blockers (RAASb) prior to randomization.
• •Concomitant coronary artery bypass graft or other valvular intervention
• •Other significant left-sided valvular heart diseases (≥moderate), even without concomitant procedure
• •Any contra-indication to CMR
• •Chronic kidney disease with estimated glomerular filtration rate (GFR) \<30 ml/min
• •Prior or planned organ transplantation
• •Hyperkaliemia (kaliemia \>5.5 mmol/L at inclusion visit)
• •Severe hepatic failure, biliary cirrhosis, cholestasis
• •Combined use of aliskiren and concomitant diabetes mellitus or renal failure with GFR\<60mL/min/1.73m²
• •Low systolic blood pressure (\<100mmHg)
• •History of angioedema
• •History of hypersensitivity or allergy to Angiotensin-II Receptor Blockers or excipient
• •Under legal authority.
• •Unwilling to consent
• •Patients not under RAASb prior to randomization but who should benefit from this treatment to improve outcome:
• •Heart failure with reduced ejection fraction (\<40%)
• •Coronary artery disease
• •Clinical peripheral artery disease
• •History of cerebrovascular disease
• •Uncontrolled hypertension despite the use of other therapeutic classes
• •Diabetes mellitus
• •Impossibility to perform randomization into the 9-day post-intervention period due to per procedural complication with prolonged stay in intensive cardiac care unit (including death).